Comparable Efficacy Of Tenofovir Versus Entecavir And Predictors Of Response In Treatment-Naïve Patients With Chronic Hepatitis B: A Multicenter Real-Life Study

Basit Öğe Kaydı
dc.authoridTR215097en_US
dc.authoridTR123671en_US
dc.authoridTR197645en_US
dc.authoridTR106278en_US
dc.authoridTR4378en_US
dc.authoridTR53380en_US
dc.authoridTR8076en_US
dc.authoridTR176024en_US
dc.contributor.authorBatirel, Ayse
dc.contributor.authorGuclu, Ertugrul
dc.contributor.authorArslan, Ferhat
dc.contributor.authorKocak, Funda
dc.contributor.authorKarabay, Oguz
dc.contributor.authorOzer, Serdar
dc.contributor.authorTuranli, Munevver
dc.contributor.authorMert, Ali
dc.date.accessioned2015-08-12T12:33:32Z
dc.date.available2015-08-12T12:33:32Z
dc.date.issued2014en_US
dc.departmentİstanbul Ticaret Üniversitesien_US
dc.description.abstractObjective: To compare responses to tenofovir (TDF) and entecavir (ETV) therapy. Methods: This was a multicenter retrospective study including treatment-naive patients with chronic hepatitis B (CHB) who received TDF or ETV. The primary end-points were undetectable HBV-DNA at 48 weeks and serological and biochemical responses. Results: Out of 195 CHB patients, 90 (46%) received TDF and 105 (54%) received ETV; 72% were male, their mean age was 43 +/- 12 years, and the mean duration of treatment was 30.2 +/- 15.7 months. Hepatitis B e antigen (HBeAg) seropositivity was 32% in the TDF group and 34% in the ETV group. HBeAg seroconversion rates in HBeAg-positive patients were 24% in the TDF group and 39% in the ETV group; the difference was not significant (p = 0.2). The mean time to alanine aminotransferase (ALT) normalization and rates of ALT normalization at 3, 6, 12, 18, and 24 months were similar in the two groups (p > 0.05). The mean time to undetectable HBV-DNA levels in the TDF and ETV groups was 11.5 +/- 8.9 and 12.9 +/- 10.8 months, respectively (p = 0.32). A significantly greater decline in HBV-DNA levels at 12 and 18 months was observed in the TDF group (p = 0.02 and p = 0.03, respectively). Seven (7%) patients on ETV therapy had virological breakthrough (p = 0.01). Only one patient in each group had hepatitis B surface antigen (HBsAg) clearance. None of the patients developed decompensation or hepatocellular carcinoma during treatment. Conclusions: The two drugs appear to have similar efficacy in CHB patients. However, 7% of patients on ETV therapy had virological breakthrough, while none of the patients on TDF therapy did. (C) 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license.en_US
dc.identifier.issn1201-9712
dc.identifier.issn1878-3511
dc.identifier.urihttps://hdl.handle.net/11467/937
dc.identifier.urihttp://dx.doi.org/10.1016/j.ijid.2014.09.004
dc.identifier.wosWOS:000348023300026en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofInternational Journal of Infectious Diseasesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectEntecavir; Tenofovir; Chronic Hepatitis B; HBV; Treatment.en_US
dc.titleComparable Efficacy Of Tenofovir Versus Entecavir And Predictors Of Response In Treatment-Naïve Patients With Chronic Hepatitis B: A Multicenter Real-Life Studyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment naïve patients with chronic hepatitis B a multicenter real life study.pdf
Boyut:
694.43 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.71 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

FEF, İstatistik Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu